STOCK TITAN

Aldeyra Therapeutics (ALDX) director receives three new stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aldeyra Therapeutics director Douglas Richard received new stock option awards. The Form 4 shows three option grants to buy Common Stock at an exercise price of $1.72 per share, covering 2,323, 19,909, and 70,000 underlying shares, respectively.

Each grant becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided he continues serving in the specified roles: as a member of the Board, as Chairperson of the Board, and as a member of the Nominating/Corporate Governance Committee.

Positive

  • None.

Negative

  • None.
Insider DOUGLAS RICHARD
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 70,000 $0.00 --
Grant/Award Stock Option (Right to Buy) 19,909 $0.00 --
Grant/Award Stock Option (Right to Buy) 2,323 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 70,000 shares (Direct, null)
Footnotes (1)
  1. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as the Chairperson of the Board of Directors of the Issuer through the applicable vesting date. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.
Option grant 1 size 2,323 shares Underlying Common Stock for first stock option grant
Option grant 2 size 19,909 shares Underlying Common Stock for second stock option grant
Option grant 3 size 70,000 shares Underlying Common Stock for third stock option grant
Exercise price <money>$1.72</money> per share Exercise price for all three stock option grants
Expiration date <date>June 8, 2036</date> Expiration for each stock option grant
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
Nominating/Corporate Governance Committee financial
"member of the Nominating/Corporate Governance Committee of the Board of Directors"
A nominating/corporate governance committee is a small group of a company’s board members tasked with choosing and evaluating directors and setting the rules that guide how the board operates. Think of it as the board’s hiring and rule-making team: it shapes leadership, board makeup, independence and ethical standards, which in turn influence how well the company is overseen and how investor interests are protected.
exercise price financial
"conversion_or_exercise_price: 1.7200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DOUGLAS RICHARD

(Last)(First)(Middle)
C/O ALDEYRA THERAPEUTICS, INC.
131 HARTWELL AVENUE

(Street)
LEXINGTON MASSACHUSETTS 02421

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aldeyra Therapeutics, Inc. [ ALDX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.7206/09/2026A70,000 (1)06/08/2036Common Stock70,000$070,000D
Stock Option (Right to Buy)$1.7206/09/2026A19,909 (2)06/08/2036Common Stock19,909$019,909D
Stock Option (Right to Buy)$1.7206/09/2026A2,323 (3)06/08/2036Common Stock2,323$02,323D
Explanation of Responses:
1. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
2. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as the Chairperson of the Board of Directors of the Issuer through the applicable vesting date.
3. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.
/s/ Richard Douglas06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Aldeyra Therapeutics (ALDX) report for Douglas Richard?

Aldeyra Therapeutics reported that director Douglas Richard received three stock option grants. These options give him the right to buy Common Stock at a fixed price, functioning as equity-based compensation tied to his board and committee service roles.

How many Aldeyra Therapeutics stock options were granted to Douglas Richard?

Douglas Richard was granted options over 2,323, 19,909, and 70,000 underlying shares. Each grant is a separate award linked to different board responsibilities, providing potential future ownership if exercised after vesting conditions are satisfied.

What is the exercise price of Douglas Richard’s Aldeyra Therapeutics stock options?

All three stock option grants carry an exercise price of $1.72 per share. This is the price at which he can buy Aldeyra Therapeutics Common Stock once the options vest and are exercisable, subject to his continued service conditions.

When do Douglas Richard’s Aldeyra Therapeutics stock options become exercisable?

Each option grant becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date. Exercisability requires Douglas Richard to maintain continuous service in the specified board, chairperson, or committee roles through that vesting date.

What roles are tied to Douglas Richard’s Aldeyra Therapeutics stock option vesting?

The vesting terms are tied to his service as a Board member, as Chairperson of the Board, and as a member of the Nominating/Corporate Governance Committee. Each grant’s exercisability depends on him remaining in the related role through the one-year vesting anniversary.